These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 19573916)

  • 1. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
    Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
    Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
    J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
    Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
    Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
    Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
    Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia.
    Kaderi MA; Norberg M; Murray F; Merup M; Sundström C; Roos G; Aleskog A; Karlsson K; Axelsson T; Tobin G; Rosenquist R
    Leukemia; 2008 Feb; 22(2):339-43. PubMed ID: 18046447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
    Idbaih A; Boisselier B; Marie Y; Sanson M; El Hallani S; Crinière E; Fourtassi M; Paris S; Carpentier C; Rousseau A; Mokhtari K; Combadière C; Laigle-Donadey F; Hoang-Xuan K; Delattre JY
    Brain Res; 2008 Mar; 1198():16-20. PubMed ID: 18262501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
    Lahiri O; Harris S; Packham G; Howell M
    Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
    Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
    Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 promotor polymorphism and disease characteristics in CLL.
    Zenz T; Benner A; Stilgenbauer S
    Leuk Res; 2010 May; 34(5):578-9. PubMed ID: 19709747
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
    Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
    Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia.
    Zenz T; Häbe S; Benner A; Kienle D; Döhner H; Stilgenbauer S
    Haematologica; 2008 Jul; 93(7):1111-3. PubMed ID: 18508789
    [No Abstract]   [Full Text] [Related]  

  • 16. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
    Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
    Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia.
    Kaderi MA; Murray F; Jansson M; Merup M; Karlsson K; Roos G; Aleskog A; Tobin G
    Leuk Res; 2008 Jun; 32(6):984-7. PubMed ID: 18006055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
    Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
    BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.
    Dharel N; Kato N; Muroyama R; Moriyama M; Shao RX; Kawabe T; Omata M
    Clin Cancer Res; 2006 Aug; 12(16):4867-71. PubMed ID: 16914573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
    Benner A; Mansouri L; Rossi D; Majid A; Willander K; Parker A; Bond G; Pavlova S; Nückel H; Merkel O; Ghia P; Montserrat E; Kaderi MA; Rosenquist R; Gaidano G; Dyer MJ; Söderkvist P; Linderholm M; Oscier D; Tvaruzkova Z; Pospisilova S; Dührsen U; Greil R; Döhner H; Stilgenbauer S; Zenz T;
    Haematologica; 2014 Aug; 99(8):1285-91. PubMed ID: 25082786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.